23rd Oct 2015 06:42
LONDON (Alliance News) - Venn Life Sciences Holdings PLC said Friday that it has won a project worth over EUR1 million with an undisclosed French biotech company.
The project is centred on acute T-cell leukaemia, Venn said, and will cover multiple regions including France, the UK and US. It will run for 33 months, and follows on from a previous trial with the same company.
"The EUR1 million project illustrates the high standard of execution for Venn's projects and how this can be used to generate repeat customer business. We have a growing client base, a strong book of business and a clear opportunity to secure more repeat business through high performance," said Chief Executive Officer Tony Richardson in a statement.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Venn Life Sciences